Skip to main content
AmigoFish

RCC Management in Localized & Metastatic Disease with Dr. Monty Pal - Rapid-Fire Rounds

From Oncology Brothers: Practice-Changing Cancer Discussions · · 18 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC).

Join us as we dived into topics including:

- The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan

- Treatment strategies for oligometastatic disease and the use of radiation

- Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and the implications of treatment breaks for patients on immuno-oncology (IO)–tyrosine kinase inhibitor (TKI) regimens

- The evolving landscape of metastatic RCC, including the comparison of IO-IO versus IO-TKI combinations and the importance of patient-centered decision-making

- The challenges and considerations in treating non–clear cell RCC, including the latest data on treatment options

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- X/Twitter: https://x.com/oncbrothers

- Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes!

#RCC, #KidneyCancer, #AdjuvantTherapy, #IO-TKI, #OncologyBrothers

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem